[go: up one dir, main page]

AR050966A1 - Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms) - Google Patents

Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms)

Info

Publication number
AR050966A1
AR050966A1 ARP050104117A ARP050104117A AR050966A1 AR 050966 A1 AR050966 A1 AR 050966A1 AR P050104117 A ARP050104117 A AR P050104117A AR P050104117 A ARP050104117 A AR P050104117A AR 050966 A1 AR050966 A1 AR 050966A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
substituted
group
heteroaryl
Prior art date
Application number
ARP050104117A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35825468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050966(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR050966A1 publication Critical patent/AR050966A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos y condiciones patologicas moduladas por el receptor de androgenos. Reivindicacion 1: Un compuesto de la formula (1) en donde R1 está seleccionado del grupo que consiste en H, alquilo C1-4, -alquil C1-4-O, -alquil C1-4-CN, -alquil C1-4-NO2, -alquil C1-4-N(RARB), -alquil C1-4-CO2H, -(alquil C1-4)-X-R7, -CH2-arilo y -CH2-heteroarilo; en donde el grupo arilo o heteroarilo (en el grupo -CH2-arilo y -CH2-heteroarilo) está opcionalmente sustituido con uno o más sustituyentes seleccionados, de modo independiente, de halogeno, alquilo C1-4, alquiloC1-4 sustituido con halogeno, alcoxi C1-4, alcoxi C1-4 sustituido con halogeno, - alquil C1-4-CN, -alquil C1-4-OH, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -S-alquilo C1-4, -S-(alquilo C1-4 sustituido con halogeno), -SO-alquilo C1-4, -SO2-alquilo C1-4, -O-aralquilo, -C(O)O-alquilo C1-4, -CO2H, -C(O)H, heteroarilo o heterocicloalquilo; en donde RA y RB están seleccionados, de modo independiente, de H o alquilo C1-4; de modo alternativo, RA y RB se toman juntos con el átomo de N al que están unidos para formar una estructura cíclica aromática, parcialmente insaturada o saturada, de 5 a 7 miembros, que contiene opcionalmente 1 o 2 heteroátomos adicionales seleccionados de O, S o N; y en donde la estructura cíclica está opcionalmente sustituida con alquilo C1-4, en donde X está seleccionado del grupo que consiste en -S-, -SO-, -SO2-, -O-SO2-, -O-, -C(OH)-, -C(=N(OH))-, -C(O)-, -C(O)-O-, -NRc-, -NRc-C(O)-, -C(O)-NRc-, -NRc-SO2- y -SO2-NRc-; en donde Rc está seleccionado de H o alquilo C1-4; en donde R7 está seleccionado del grupo que consiste en alquilo C1-4, alquilo C1-4 sustituido con halogeno, alquenilo C2-4, arilo, aralquilo, bifenilo, cicloalquilo, cicloalquil-(alquilo C1-4)-, heteroarilo, heteroaril-(alquilo C1-4)-, heterocicloalquilo y heterocicloaquil-(alquilo C1-4)-; en donde el grupo cicloalquilo, arilo, heteroarilo o heterocicloalquilo, ya sea solo o como parte de un grupo sustituyente, está opcionalmente sustituido con 1 o más sustituyentes seleccionados, de modo independiente, de halogeno, hidroxi, carboxi, alquilo C1-4, alquilo C1-4 sustituido con halogeno, alcoxi C1-4, alcoxi C1-4 sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -S(O)0-2-(alquilo C1-4), -SO2-N(RD)2, arilo, heteroarilo o heterocicloalquilo; en donde cada RD está seleccionado, de modo independiente, de H o alquilo C1-4; con la condicion de que, cuando X es O o NRc, R6 sea distinto de alquenilo C2-4; R2 está seleccionado del grupo que consiste en H, halogeno, alquilo C1-4, alquilo C1-4 sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -O-alquilo C1-4, -S-alquilo C1-4, -SO-alquilo C1-4, -SO2-alquilo C1-4 y -NRE-C(O)-alquilo C1-4; en donde RE está seleccionado de H o alquilo C1-4; R3 está seleccionado del grupo que consiste en H, halogeno, alquilo C1-4, alquilo C1-4 sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -O-alquilo C1-4, -S-alquilo C1-4, -SO-alquilo C1-4, -SO2-alquilo C1-4 y -NRF-C(O)- alquilo C1-4; en donde RF está seleccionado de H o alquilo C1-4; con la condicion de que al menos uno de R2 o R3 sea distinto de H; a es un numero entero de 0 a 1; R4 está seleccionado del grupo que consiste en H, alquilo C1-4, alquilo C1-4 sustituido con halogeno y -C(O)-R8; en donde R8 está seleccionado del grupo que consiste en alquilo C1-4, cicloalquilo, cicloalquil-(alquilo C1-4)-, arilo, aralquilo, heteroarilo, heteroaril-(alquilo C1-4)-, heterocicloalquilo y heterocicloalquil- (alquilo C1-4)-, en donde el grupo alquilo, cicloalquilo, arilo, heteroarilo o heterocicloalquilo, ya sea solo o como parte de un grupo sustituyente, está opcionalmente sustituido con uno o más sustituyentes seleccionados, de modo independiente, de halogeno, hidroxi, carboxi, alquilo C1-4, alquilo C1-4 sustituido con halogeno, alcoxi C1-4, alcoxi C1-4 sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4 o di(alquil C1-4)amino; R5 está seleccionado del grupo que consiste en H, halogeno, alquilo C1-4 y alquilo C1-4 sustituido con halogeno; R6 está seleccionado el grupo que consiste en alquilo C1-4, alquilo C1-4 sustituido con halogeno, -alquil C1-4-OH, -alquil C1-4-CN, -alquil C1-4-NO2, -alquil C1-4-N(RGRH), alquil C1-4- CO2H, -(alquil C1-4)-Y-R9, -CH2-arilo y -CH2-heteroarilo; en donde el arilo o heteroarilo (en el grupo -CH2-arilo o -CH2-heteroarilo) está opcionalmente sustituido con uno o más sustituyentes seleccionados, de modo independiente, de halogeno, hidroxi, alquilo C1-4, alquilo C1-4 sustituido con halogeno, alcoxi C1-4, alcoxi C1-4- sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -S(O)0-2-alquilo C1-4 o -SO2-N(RJ)2; en donde cada RJ está seleccionado, de modo independiente, de H o alquilo C1-4; en done RG y RH están seleccionados, de modo independiente, de H o alquilo C1-4; de modo alternativo, RG y RH se toman juntos con el átomo de N al que están unidos para formar una estructura cíclica aromática, parcialmente insaturada o saturada, de 5 a 7 miembros, que contiene opcionalmente 1 o 2 heteroátomos adicionales seleccionados de O, S o N; y en donde la estructura cíclica está opcionalmente sustituida con alquilo C1-4; en donde Y está seleccionado del grupo que consiste en -S-, -SO-, SO2-, -O-SO2-, -O-, -C(OH)-, -C(=N(OH))-, -C(O)-, -C(O)-O-, -NRk-, -NRk-C(O)-, -C(O)-NRk-, -NRk-SO2- y -SO2-NRk-; en donde Rk está seleccionado de H o alquilo C1-4; en donde R9 está seleccionado del grupo que consiste en alquilo C1-4, alquilo C1-4 sustituido con halogeno, alquenilo C2-4, arilo, aralquilo, bifenilo, cicloalquilo, cicloalquil-(alquilo C1-4)-, heteroarilo, heteroaril-(alquilo C1-4)-, heterocicloalquilo y heterocicloaquil-(alquilo C1-4)-; en donde el grupo cicloalquilo, arilo, heteroarilo o heterocicloalquilo, ya sea solo o como parte de un grupo sustituyente, está opcionalmente sustituido con 1 o más sustituyentes seleccionados, de modo independiente, de halogeno, hidroxi, carboxi, alquilo C1-4, alquilo C1-4 sustituido con halogeno, alcoxi C1-4, alcoxi C1-4 sustituido con halogeno, ciano, nitro, amino, alquilamino C1-4, di(alquil C1-4)amino, -S(O)0-2-(alquilo C1-4), -SO2-N(RL)2 o -NRM-C(O)-alquilo C1-4; en donde cada RL está seleccionado, de modo independiente, de H o alquilo C1-4; y en donde RM está seleccionado de H o alquilo C1-4; con la condicion de que, cuando Y es O o NRk, R9 sea distinto de alquenilo C2-4; con la condicion de que, cuando R4 es H y R5 es H, R6 sea distinto de alquilo C1-4; también con la condicion de que, cuando R1 es H; a es 0; R4 es H y R5 es alquilo C1-4; R6 sea distinto de alquilo C1-4; también con la condicion de que, cuando R1 es H, a es 0; R2 es -O-alquilo C1-4; R3 es H; R4 es H; R5 es H; R6 sea distinto de -CH2-fenilo, en donde el fenilo está sustituido con -O-alquilo C1-4; también con la condicion de que, cuando R1 es H, a es 0, R4 es H y R5 es H, R6 sea distinto de -CH2-(bencimidazolilo), en donde el bencimidazolilo está sustituido con 1 a 2 sustituyentes seleccionados de halogeno, alquilo C1-4 u -O-alquilo C1-4; o una de sus sales farmacéuticamente aceptables.
ARP050104117A 2004-09-30 2005-09-29 Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms) AR050966A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61475104P 2004-09-30 2004-09-30

Publications (1)

Publication Number Publication Date
AR050966A1 true AR050966A1 (es) 2006-12-06

Family

ID=35825468

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104117A AR050966A1 (es) 2004-09-30 2005-09-29 Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms)

Country Status (10)

Country Link
US (3) US7566733B2 (es)
EP (1) EP1805147B1 (es)
JP (1) JP4953456B2 (es)
CN (1) CN101065363B (es)
AR (1) AR050966A1 (es)
AU (1) AU2005292345B9 (es)
CA (1) CA2582356A1 (es)
MY (1) MY147985A (es)
TW (1) TW200621725A (es)
WO (1) WO2006039243A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945183B2 (en) 2004-10-20 2015-02-03 Vertiflex, Inc. Interspinous process spacer instrument system with deployment indicator
US8864828B2 (en) 2004-10-20 2014-10-21 Vertiflex, Inc. Interspinous spacer
US8613747B2 (en) 2004-10-20 2013-12-24 Vertiflex, Inc. Spacer insertion instrument
US8123807B2 (en) 2004-10-20 2012-02-28 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8277488B2 (en) 2004-10-20 2012-10-02 Vertiflex, Inc. Interspinous spacer
US8167944B2 (en) 2004-10-20 2012-05-01 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8273108B2 (en) 2004-10-20 2012-09-25 Vertiflex, Inc. Interspinous spacer
US8012207B2 (en) 2004-10-20 2011-09-06 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8317864B2 (en) 2004-10-20 2012-11-27 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US8128662B2 (en) 2004-10-20 2012-03-06 Vertiflex, Inc. Minimally invasive tooling for delivery of interspinous spacer
US8409282B2 (en) 2004-10-20 2013-04-02 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
US8152837B2 (en) 2004-10-20 2012-04-10 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US9119680B2 (en) 2004-10-20 2015-09-01 Vertiflex, Inc. Interspinous spacer
US9161783B2 (en) 2004-10-20 2015-10-20 Vertiflex, Inc. Interspinous spacer
US8123782B2 (en) 2004-10-20 2012-02-28 Vertiflex, Inc. Interspinous spacer
US7763074B2 (en) 2004-10-20 2010-07-27 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for posterior dynamic stabilization of the spine
US9023084B2 (en) 2004-10-20 2015-05-05 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for stabilizing the motion or adjusting the position of the spine
US8425559B2 (en) 2004-10-20 2013-04-23 Vertiflex, Inc. Systems and methods for posterior dynamic stabilization of the spine
ATE417830T1 (de) * 2004-11-02 2009-01-15 Pfizer Sulfonylbenzimidazolderivate
WO2009086010A2 (en) 2004-12-06 2009-07-09 Vertiflex, Inc. Spacer insertion instrument
PT1984343E (pt) * 2006-01-24 2013-05-15 Janssen Pharmaceutica Nv Benzimidazóis 2-substituída como moduladores seletivos do recetor de andrógeno (sarm)
US8845726B2 (en) 2006-10-18 2014-09-30 Vertiflex, Inc. Dilator
EP2155121B1 (en) 2007-04-16 2015-06-17 Vertiflex, Inc. Interspinous spacer
MX2009011281A (es) * 2007-04-20 2010-03-08 Univ New York State Res Found Benzimidazol y composiciones farmaceuticas del mismo.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
WO2009123164A1 (ja) * 2008-04-02 2009-10-08 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するヘテロ環誘導体
WO2011084477A2 (en) 2009-12-15 2011-07-14 Vertifex, Inc. Spinal spacer for cervical and other vertebra, and associated systems and methods
WO2011097496A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
WO2013116823A1 (en) * 2012-02-02 2013-08-08 The Research Foundation Of State University Of New York Benzimidazoles and uses thereof
US9675303B2 (en) 2013-03-15 2017-06-13 Vertiflex, Inc. Visualization systems, instruments and methods of using the same in spinal decompression procedures
WO2015138611A2 (en) 2014-03-11 2015-09-17 Colorado State University Research Foundation Methods for improved in vitro-in vivo efficacy determination
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
US10524772B2 (en) 2014-05-07 2020-01-07 Vertiflex, Inc. Spinal nerve decompression systems, dilation systems, and methods of using the same
ES3028873T3 (en) 2015-01-17 2025-06-20 Univ Texas Small molecules for the treatment of primary cancer and cancer metastasis
CA3027563C (en) 2016-06-22 2024-07-02 Ellipses Pharma Ltd AR+ METHODS FOR BREAST CANCER TREATMENT
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
WO2019079691A1 (en) 2017-10-19 2019-04-25 Jean Jiang SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
PH12021551950A1 (en) 2019-02-12 2022-05-23 Radius Pharmaceuticals Inc Processes and compounds
US12102542B2 (en) 2022-02-15 2024-10-01 Boston Scientific Neuromodulation Corporation Interspinous spacer and methods and systems utilizing the interspinous spacer
US12433646B2 (en) 2023-02-21 2025-10-07 Boston Scientific Neuromodulation Corporation Interspinous spacer with actuator locking arrangements and methods and systems
US12390340B2 (en) 2023-03-15 2025-08-19 Boston Scientific Neuromodulation Corporation Interspinous spacer with a range of deployment positions and methods and systems
CN120230046A (zh) * 2023-12-29 2025-07-01 杭州壹瑞医药科技有限公司 Trpv3抑制剂及其制备和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE947610C (de) 1955-04-30 1956-08-23 Basf Ag Verfahren zur Herstellung von Benzimidazoinen
US3325271A (en) * 1963-07-17 1967-06-13 United States Borax Chem Herbicidal composition and method employing substituted benzimidazoles
US3897432A (en) * 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
SE357932B (es) 1972-01-27 1973-07-16 Malaga Ab
US3987182A (en) 1974-06-17 1976-10-19 Schering Corporation Novel benzimidazoles useful as anti-androgens
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
JPH05163246A (ja) 1991-12-17 1993-06-29 Nippon Oil & Fats Co Ltd ペルフルオロ−オキサ−アルキル基含有ベンズイミダゾール誘導体及びその製造方法
GB9310069D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
EP1805147B1 (en) 2014-08-13
JP2008514707A (ja) 2008-05-08
CA2582356A1 (en) 2006-04-13
TW200621725A (en) 2006-07-01
MY147985A (en) 2013-02-28
CN101065363B (zh) 2012-05-02
AU2005292345B9 (en) 2011-12-15
US7566733B2 (en) 2009-07-28
JP4953456B2 (ja) 2012-06-13
US20090258909A1 (en) 2009-10-15
AU2005292345B2 (en) 2011-12-01
CN101065363A (zh) 2007-10-31
US7879895B2 (en) 2011-02-01
AU2005292345A1 (en) 2006-04-13
US20110086883A1 (en) 2011-04-14
WO2006039243A1 (en) 2006-04-13
US8586616B2 (en) 2013-11-19
EP1805147A1 (en) 2007-07-11
US20060116412A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
AR050966A1 (es) Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms)
AR048643A1 (es) Derivados de indol como moduladores selectivos de los receptores androgenicos (sarms)
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
AR004225A1 (es) Derivados de indolin-2-ona, su uso, un procedimiento para prepararlos, composiciones farmaceuticas que los comprenden y compuestos utiles como intermediarios para preparar dichos derivados
AR040030A1 (es) Moduladores biciclicos de la funcion del receptor de androgeno
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR062640A1 (es) Compuestos de azolcarboxamidas y composiciones herbicidas
AR055177A1 (es) Compuestos heterociclicos fusionados utiles como moduladores de cinasa
AR078793A1 (es) Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
AR043436A1 (es) Tetrahidroisoquinolinas sustituidas para uso como moduladores 5-ht6
AR050967A1 (es) Derivados de bencimidazol utiles como moduladores de los receptores androgenicos (sarms)
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
AR064521A1 (es) Activador de glucoquinasa
ECSP088648A (es) Nuevos bencimidazoles 2-sustituidos como moduladores de receptor de androgeno selectivos (sarms)
CU20090072A7 (es) Ácido l-glutámico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, así como procedimientos para su preparación
ECSP088457A (es) Compuestos de benzamida útiles como inhibidores de la histona deacetilasa
AR020165A1 (es) Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos
AR055202A1 (es) Derivados de imidazolcarboxamida como inhibidores de fructosa -1,6- biofosfatasa y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration